74 related articles for article (PubMed ID: 15998523)
1. Expression of p53 in renal carcinoma cells is independent of pVHL.
Stickle NH; Cheng LS; Watson IR; Alon N; Malkin D; Irwin MS; Ohh M
Mutat Res; 2005 Oct; 578(1-2):23-32. PubMed ID: 15998523
[TBL] [Abstract][Full Text] [Related]
2. Influence of the RNA-binding protein HuR in pVHL-regulated p53 expression in renal carcinoma cells.
Galbán S; Martindale JL; Mazan-Mamczarz K; López de Silanes I; Fan J; Wang W; Decker J; Gorospe M
Mol Cell Biol; 2003 Oct; 23(20):7083-95. PubMed ID: 14517280
[TBL] [Abstract][Full Text] [Related]
3. Tissue-specific expression of SV40 in tumors associated with the Li-Fraumeni syndrome.
Malkin D; Chilton-MacNeill S; Meister LA; Sexsmith E; Diller L; Garcea RL
Oncogene; 2001 Jul; 20(33):4441-9. PubMed ID: 11494139
[TBL] [Abstract][Full Text] [Related]
4. Autocrine interleukin-6 production in renal cell carcinoma: evidence for the involvement of p53.
Angelo LS; Talpaz M; Kurzrock R
Cancer Res; 2002 Feb; 62(3):932-40. PubMed ID: 11830554
[TBL] [Abstract][Full Text] [Related]
5. Antitumor effect of parathyroid hormone-related protein neutralizing antibody in human renal cell carcinoma in vitro and in vivo.
Talon I; Lindner V; Sourbier C; Schordan E; Rothhut S; Barthelmebs M; Lang H; Helwig JJ; Massfelder T
Carcinogenesis; 2006 Jan; 27(1):73-83. PubMed ID: 16081513
[TBL] [Abstract][Full Text] [Related]
6. Mutant p53 expression in kidney tubules adjacent to renal cell carcinoma: evidence of a precursor lesion.
Lai R; el Dabbagh L; Mourad WA
Mod Pathol; 1996 Jun; 9(6):690-5. PubMed ID: 8782209
[TBL] [Abstract][Full Text] [Related]
7. Synergy of interferon-alpha and 5-fluorouracil in human renal cell carcinoma requires p53 activity.
Shang D; Ito N; Watanabe J; Awakura Y; Nishiyama H; Kamoto T; Ogawa O
Eur Urol; 2007 Oct; 52(4):1131-9. PubMed ID: 17275163
[TBL] [Abstract][Full Text] [Related]
8. [Expression of S100 protein in renal cell carcinoma and its relation with P53].
Yang JF; Zhang XY; Qi F
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2004 Jun; 29(3):301-4. PubMed ID: 16136965
[TBL] [Abstract][Full Text] [Related]
9. Biological aspects and binding strategies of vascular endothelial growth factor in renal cell carcinoma.
Rini BI; Rathmell WK
Clin Cancer Res; 2007 Jan; 13(2 Pt 2):741s-746s. PubMed ID: 17255303
[TBL] [Abstract][Full Text] [Related]
10. Expression of p53 isoforms in renal cell carcinoma.
Song W; Huo SW; Lü JJ; Liu Z; Fang XL; Jin XB; Yuan MZ
Chin Med J (Engl); 2009 Apr; 122(8):921-6. PubMed ID: 19493415
[TBL] [Abstract][Full Text] [Related]
11. Negative regulation of chemokine receptor CXCR4 by tumor suppressor p53 in breast cancer cells: implications of p53 mutation or isoform expression on breast cancer cell invasion.
Mehta SA; Christopherson KW; Bhat-Nakshatri P; Goulet RJ; Broxmeyer HE; Kopelovich L; Nakshatri H
Oncogene; 2007 May; 26(23):3329-37. PubMed ID: 17130833
[TBL] [Abstract][Full Text] [Related]
12. Expression and regulation of non-classical HLA-G in renal cell carcinoma.
Dunker K; Schlaf G; Bukur J; Altermann WW; Handke D; Seliger B
Tissue Antigens; 2008 Aug; 72(2):137-48. PubMed ID: 18721274
[TBL] [Abstract][Full Text] [Related]
13. Molecular pathways in renal cell carcinoma--rationale for targeted treatment.
Kim WY; Kaelin WG
Semin Oncol; 2006 Oct; 33(5):588-95. PubMed ID: 17045088
[TBL] [Abstract][Full Text] [Related]
14. Clinical implications of hypoxia inducible factor in renal cell carcinoma.
Smaldone MC; Maranchie JK
Urol Oncol; 2009; 27(3):238-45. PubMed ID: 19414111
[TBL] [Abstract][Full Text] [Related]
15. p53 pathway in renal cell carcinoma is repressed by a dominant mechanism.
Gurova KV; Hill JE; Razorenova OV; Chumakov PM; Gudkov AV
Cancer Res; 2004 Mar; 64(6):1951-8. PubMed ID: 15026329
[TBL] [Abstract][Full Text] [Related]
16. Transglutaminase 2 inhibition found to induce p53 mediated apoptosis in renal cell carcinoma.
Ku BM; Kim DS; Kim KH; Yoo BC; Kim SH; Gong YD; Kim SY
FASEB J; 2013 Sep; 27(9):3487-95. PubMed ID: 23704086
[TBL] [Abstract][Full Text] [Related]
17. Paclitaxel/Taxol sensitivity in human renal cell carcinoma is not determined by the p53 status.
Reinecke P; Kalinski T; Mahotka C; Schmitz M; Déjosez M; Gabbert HE; Gerharz CD
Cancer Lett; 2005 May; 222(2):165-71. PubMed ID: 15863265
[TBL] [Abstract][Full Text] [Related]
18. PSF-TFE3 oncoprotein in papillary renal cell carcinoma inactivates TFE3 and p53 through cytoplasmic sequestration.
Mathur M; Das S; Samuels HH
Oncogene; 2003 Aug; 22(32):5031-44. PubMed ID: 12902986
[TBL] [Abstract][Full Text] [Related]
19. The sensitivity of renal cell carcinoma cells to interferon alpha correlates with p53-induction and involves Bax.
Wittnebel S; Jalil A; Thiery J; DaRocha S; Viey E; Escudier B; Chouaib S; Caignard A
Eur Cytokine Netw; 2005 Jun; 16(2):123-7. PubMed ID: 15941683
[TBL] [Abstract][Full Text] [Related]
20. Identification and functional characterization of pVHL-dependent cell surface proteins in renal cell carcinoma.
Boysen G; Bausch-Fluck D; Thoma CR; Nowicka AM; Stiehl DP; Cima I; Luu VD; von Teichman A; Hermanns T; Sulser T; Ingold-Heppner B; Fankhauser N; Wenger RH; Krek W; Schraml P; Wollscheid B; Moch H
Neoplasia; 2012 Jun; 14(6):535-46. PubMed ID: 22806541
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
